Insmed Incorporated (NASDAQ:INSM) COO Sells $100,125.04 in Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 1,457 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total transaction of $100,125.04. Following the transaction, the chief operating officer now directly owns 146,082 shares in the company, valued at approximately $10,038,755.04. This represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The shares were sold at an average price of $63.68, for a total value of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total value of $161,181.80.

Insmed Price Performance

Shares of Insmed stock traded up $2.55 during trading on Thursday, hitting $72.75. The stock had a trading volume of 2,264,024 shares, compared to its average volume of 2,139,833. The firm has a market cap of $13.01 billion, a price-to-earnings ratio of -13.11 and a beta of 1.12. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The business’s 50-day moving average is $71.18 and its 200 day moving average is $72.47. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the prior year, the firm posted ($1.10) earnings per share. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Hedge funds have recently bought and sold shares of the stock. Capital CS Group LLC purchased a new stake in shares of Insmed during the 4th quarter valued at $586,000. Orion Portfolio Solutions LLC raised its position in Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC lifted its stake in Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after purchasing an additional 21,833 shares during the last quarter. Vestal Point Capital LP lifted its position in Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock worth $116,800,000 after buying an additional 850,000 shares during the last quarter. Finally, TimesSquare Capital Management LLC purchased a new stake in shares of Insmed in the 3rd quarter valued at $35,322,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on INSM shares. Bank of America upped their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Truist Financial reiterated a “buy” rating and set a $105.00 price target (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.